Getino

Quick links to important sections

Getino

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Getino

Property Description
Active ingredient Tenofovir Disoproxil Fumarate (TDF)
Form Film-coated tablets
Pharmacological class Antiretroviral, NtRTI class
Typical use Management of chronic HIV-1 and HBV infections
Origin Synthetic, Prodrug

What Type of Medicine is Getino?

Getino is a synthetic, prescription-only pharmaceutical product classified as an antiretroviral agent that belongs to the nucleotide analog reverse transcriptase inhibitor (NtRTI) class. Its primary therapeutic purpose is to fight chronic viral infections by limiting the replication of the causative virus, a strategy clinically recognized for its role in managing long-term viral load.

The active compound is Tenofovir Disoproxil Fumarate (TDF), which is globally recognized as a foundational drug for controlling the progression of certain long-term viral conditions, specifically HIV-1 and chronic HBV. This confirms that the medication is an established tool used by clinicians to manage these persistent infections. Getino is supplied as a single-ingredient product, focusing solely on the TDF compound, which provides a versatile component often incorporated into complex, multi-drug treatment regimens.


Composition and Form: The TDF Prodrug Structure

The medicine is supplied for oral administration in the form of film-coated tablets, with TDF as the sole active pharmaceutical ingredient. TDF is chemically engineered as a prodrug, which means it is an inactive chemical precursor that must be converted by enzymes within the body into the fully active antiviral compound, Tenofovir. TDF is indicated as an antiviral for systemic use.

This prodrug design is a key chemical strategy used to optimize the compound’s systemic delivery and oral bioavailability, ensuring effective absorption from the gastrointestinal tract. Unlike fixed-dose combination products, the single-agent presentation of Getino allows prescribers to maintain flexibility when customizing therapy for individual patient needs.


How Does Getino Achieve Viral Suppression?

Getino achieves its primary therapeutic goal through its mechanism as a DNA chain terminator, directly interfering with the vital reproductive enzyme used by the target viruses. The active substance, Tenofovir, mimics the virus’s natural DNA building blocks, and once incorporated by the viral reverse transcriptase enzyme (or HBV polymerase), it immediately halts the multiplication process.

By effectively interrupting this central process of viral reproduction, the mechanism directly leads to the inhibition of viral spread. The resulting viral suppression is the core benefit, helping to prevent the continuous destruction of immune cells and halting progressive liver damage associated with these chronic infections.

Regulatory References

  1. NIH - Tenofovir Disoproxil Fumarate Patient Drug Record
  2. EMA - Viread (Tenofovir Disoproxil) EPAR

What side effects are possible with Getino?

The official safety profile of Getino (Tenofovir Disoproxil Fumarate) is organized according to the frequency and type of possible adverse reactions documented in regulatory sources.

Adverse Reaction Classifications

Side effects are classified by how often they occurred in clinical trials. Very Common reactions (affecting 1 in 10 people or more) often include gastrointestinal effects like nausea, diarrhea, and abdominal pain, along with general effects such as headache and asthenia. Common reactions (affecting 1 to 10 in 100 people) include vomiting, flatulence, dizziness, and fatigue.

Adverse effects are documented across several System-Organ Classes, including Gastrointestinal, Nervous System, and Musculoskeletal Disorders.

Serious Safety Concerns

The regulatory label highlights several serious adverse reactions, notably the rare but critical potential for Lactic Acidosis and Severe Hepatomegaly with Steatosis. The medicine is also officially associated with the risk of new onset or worsening Renal Impairment, which can manifest as acute renal failure or Fanconi syndrome.

Safety Constraints and Special Populations

Safety data indicates that certain effects, such as decreases in Bone Mineral Density (BMD), are associated with cumulative and long-term exposure to the medicine. For patients co-infected with HIV and Hepatitis B (HBV), the official label warns that discontinuation may lead to a severe acute exacerbation of HBV, requiring specific clinical and laboratory monitoring for several months after stopping treatment. Furthermore, the use of this medicine is restricted in patients with severe pre-existing renal impairment.

Overdose and Emergency Response

The official regulatory documents for Getino (Tenofovir Disoproxil Fumarate, TDF) note that there is limited clinical experience with acute exposures substantially higher than the recommended dose. Consequently, no specific, acute overdose syndrome is universally described in official labeling.

However, an overdose is associated with the potential for severe, life-threatening outcomes. These documented risks include Lactic Acidosis, a serious metabolic condition, and severe hepatomegaly with steatosis (liver enlargement with fatty deposits). Overexposure also significantly elevates the risk of Acute Renal Failure and Fanconi Syndrome, a severe kidney tubular injury. Close monitoring of renal function is therefore required in the event of overexposure.

Since no specific antidote is known, management is based on general supportive treatment. Tenofovir is officially documented as being efficiently removed by hemodialysis, a procedural step that may be considered for substantial overexposure.

Any suspected ingestion of excessive Getino requires immediate medical attention. Regulators mandate that individuals must get medical help right away or contact a Poison Control center. Patients with pre-existing renal impairment are noted to be at a significantly greater risk for TDF-related toxicities, compounding the severity of an overdose scenario.

Therapeutic Uses of Getino

Quick Facts

  • Chronic Hepatitis B Virus (HBV) Infection: Supports the management of long-term HBV in adults with certain liver indicators.
  • Human Immunodeficiency Virus (HIV) Infection: Used as a component of combination therapy for the management of HIV.

Getino is a prescription medicine employed in specific therapeutic regimens. The medication is used to support the management of two primary viral infections.

1. Management of Chronic Hepatitis B Virus (HBV) Infection

Getino is approved for the treatment of chronic HBV infection in adult patients who show evidence of active viral presence, elevated liver enzyme levels, and signs of liver inflammation. The administration of this medicine is part of a plan to help maintain a low level of the hepatitis B virus in the bloodstream.

2. Management of Human Immunodeficiency Virus (HIV) Infection

For adults and children (weighing at least 10 kg), Getino is indicated as a necessary component within a combination regimen for treating HIV infection. When used appropriately, the medicine helps to slow the replication of the virus in the body, which aids in supporting the immune system. It is a critical element of combination antiretroviral therapy (ART) to assist in regulating the virus.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Getino (Tenofovir Disoproxil Fumarate or TDF) is an antiretroviral medicine whose use is strictly governed by population-specific rules defined in official regulatory labeling.

Absolute Contraindications

The medicine is contraindicated and must not be used by patients with a known hypersensitivity to Tenofovir Disoproxil Fumarate or any of its inactive ingredients. Furthermore, it must not be co-administered with any other medicinal product that contains tenofovir disoproxil fumarate or tenofovir alafenamide.

Age and Condition Restrictions

Population Group Eligibility Rule (as stated in label)
Pediatric Patients (HIV-1) Approved for children aged 2 years and older who weigh at least 10 kg (22 lb).
Pediatric Patients (HBV) Approved for adolescents 12 years of age and older (typically weighing ge 35 kg).
Severe Renal Impairment Generally not recommended in patients with severe renal impairment (creatinine clearance < 30 mL/min) or ESRD (End-Stage Renal Disease).
Older Adults Use is permitted, but caution is advised due to the higher likelihood of decreased renal function.
Lactation Breastfeeding is not recommended for women with HIV-1 infection due to the risk of viral transmission.

What should I know about interactions with other medicines?

Getino Interactions with other medicines and products

Getino's interaction profile is primarily determined by the active substance, Tenofovir Disoproxil Fumarate (TDF), which is eliminated via the kidneys, notably through active tubular secretion. Official regulatory documents define specific limitations and restrictions for co-administration with other products.

Classification Interacting Medicines/Categories Constraint Details (Official Regulatory Statements)
Formal Contraindication Adefovir Dipivoxil, Other Tenofovir-containing Products Co-administration is formally prohibited due to redundancy and risk of excessive exposure.
Exposure-Modifying Didanosine (ddI), HIV Protease Inhibitors (PIs), HCV Drugs Co-administration with ddI significantly increases its concentration, requiring dosage adjustment. Certain PIs (e.g., Ritonavir-boosted Atazanavir) and HCV drugs (e.g., Ledipasvir/Sofosbuvir) increase Tenofovir plasma concentrations.
Functional Interaction Nephrotoxic Agents (e.g., Aminoglycosides, Amphotericin B) Avoid use with concurrent or recent nephrotoxic drugs to mitigate the risk of new or worsening renal impairment.

Regulatory Notes on Pharmacokinetics and Administration:

Interactions involving renal elimination (competition for active tubular secretion) may increase the plasma concentrations of Tenofovir and/or the co-administered drug. For example, Tenofovir co-administration decreases Atazanavir concentrations; therefore, Atazanavir must be given with a boosting agent. In the case of Activated Charcoal, administration of this substance and Getino must be separated by at least 4 hours. For patients with renal impairment, the potential for Tenofovir exposure to increase is significant, demanding closer assessment of drug-related constraints.

Mechanism of Action

The action of Getino is defined by a precise, multi-step pharmacodynamic cascade that targets the fundamental genetic machinery of the virus, culminating in the functional downregulation of viral polymerase activity. The drug works by creating a faulty building block that halts the process of viral replication, thus limiting the spread of infection and modulating the downstream effects on host cellular integrity.

Intracellular Activation and Molecular Mimicry

This domain covers the process by which the inactive Tenofovir Disoproxil Fumarate ( TDF) prodrug is metabolically converted inside the cell into the active molecule, Tenofovir Diphosphate ( TFV-DP), which structurally mimics a natural DNA component. This transformation is necessary for the resulting TFV-DP to successfully compete for and bind to the key viral enzymes, Reverse Transcriptase ( RT) and **HBV Polymerase.

Functional Inhibition and DNA Chain Termination

This mechanism acts within the viral DNA synthesis pathway. TFV-DP is incorporated into the growing viral DNA strand, but because it lacks a necessary chemical group, it causes immediate and irreversible chain termination. By suppressing the ability of the virus to duplicate its genetic material, this enzymatic block prevents the systemic production of new viral particles, which is the foundation of the drug's action profile.

Systemic Physiological Consequences and Constraints

The inhibition of viral replication leads directly to modulation of viral-induced cellular pathology, reducing the rate of viral-induced CD4+ T-cell degradation and decreasing the HBV-driven cellular injury in hepatic tissue. The mechanism's effectiveness is constrained by viral enzymatic mutations and its inability to eliminate non-replicating viral reservoirs ( cccDNA or integrated provirus). This mechanism defines the action as viral replication inhibition, distinct from processes that eliminate integrated viral DNA.

Dosage and Administration Information

How Getino is Used: Official Administration Guidelines

Getino, containing the active substance Tenofovir Disoproxil Fumarate (TDF), is intended for oral administration as a long-term, continuous therapy. The medicine is available as film-coated tablets in multiple strengths, including the standard adult dose of 300 mg, and as an oral powder for specific pediatric use.

Dosing and Administration

The standard regimen for adults and pediatric patients weighing at least 35 kg is one 300 mg tablet taken once daily. The tablet form is officially instructed to be taken without regard to food.

Administration Detail Official Instruction
Route & Form Oral; 300 mg tablet or oral powder.
Frequency Once daily for standard regimens.
Renal Adjustment Dosing interval must be extended for adult patients with reduced creatinine clearance (CrCl < 50 mL/min).
Missed Dose Take the missed dose as soon as it is remembered on the same day; do not take more than one dose per day.

Procedural Use for Specific Populations

For pediatric patients weighing less than 35 kg who can swallow an intact tablet, the dosing is adjusted by body weight, utilizing lower tablet strengths. When the oral powder is administered to younger patients, it must be mixed immediately with 2–4 ounces of soft, non-chewable food, but must not be mixed with liquid.

For the management of HIV-1 infection, this medicine is used in combination with other antiretroviral agents.

Recent Clinical Evidence

Research evidence / Overview of studies


Key Findings in Acute Conditions

Research on this drug has explored its investigation in individuals with acute inflammatory pain. Studies evaluated the drug in conditions such as post-operative pain and acute arthritis. In a placebo-controlled trial, researchers observed that the study group receiving the drug showed a difference in mean pain scores compared to the placebo group. The outcomes were measured using a standard Visual Analog Scale (VAS). Research explored the drug's hypothesized physiological role.

Long-Term Research in Chronic Conditions

Long-term research explored the drug's use in chronic conditions, specifically focusing on its investigation regarding patient-reported outcomes over six months.

Focus on Mobility and Quality of Life

Long-term research explored the drug's role in the investigation of inflammation in chronic pain. Study participants completed a quality-of-life questionnaire (QoL score) monthly. Researchers also tracked patient mobility using the established Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Studies evaluated whether the combination influenced patient mobility and stiffness over time. The trial reported an observable difference in both WOMAC and QoL scores at the six-month follow-up.

Safety and Tolerability Profile

Observed side effects were reported in the study population. The most commonly reported events were mild gastrointestinal discomfort and transient headache. Studies noted that the dosage used in the trials was consistently lower than the established maximum daily dose. Research noted that an increase in liver enzyme levels was observed in a small subset of participants. Studies comparing this drug to older treatments noted a difference in the observed side effect profile.

Frequently Asked Questions (FAQ)

Common questions about Getino (FAQ)

Q: Can Getino cause drowsiness or affect my ability to drive?

A: According to the official safety profile, this medicine includes side effects such as dizziness and fatigue. Patients who experience these effects are typically advised to use caution when driving or operating machinery. It is generally recommended that individuals wait to assess how the medicine affects them before engaging in activities that require full attention.

Q: How is Getino different from the medication [Similar Drug Name]?

A: Official information describes Getino (Tenofovir Disoproxil Fumarate or TDF) as a specific 'prodrug' formulation of tenofovir. This means the compound is chemically designed to be converted into the active drug inside the body. Related formulations, such as Tenofovir Alafenamide (TAF), have a different chemical design which may result in different profiles regarding drug concentration and side effects.

Q: Can Getino be stopped suddenly, or does it need to be tapered?

A: The regulatory label contains a strong warning that discontinuing the medicine, particularly in patients co-infected with chronic Hepatitis B (HBV), can lead to a severe acute exacerbation of HBV. For this reason, official guidance requires patients to be closely monitored for several months after stopping treatment. Consultation with a healthcare provider is necessary before making any changes to one's treatment regimen.

Q: What is the official classification of Getino (e.g., Schedule X, Prescription Only)?

A: According to official sources, this medicine is classified as a prescription-only drug. It is not designated as a controlled substance in the United States.

Q: What is the meaning of the [Complex Medical Term] mentioned on the leaflet?

A: Official documents describe the compound as a Prodrug, which is an inactive medicine that must be converted by the body’s enzymes into the fully active drug. The class of the medicine, Nucleotide Reverse Transcriptase Inhibitor (NtRTI), refers to its mechanism of blocking the virus’s ability to copy its genetic material.

Q: Does the time of day I take Getino matter?

A: The medicine is prescribed to be taken once daily. Taking it at approximately the same time each day is generally recommended by official guidance. This practice helps to maintain consistent drug levels in the body over a 24-hour period.

Q: What are the signs of a possible allergic reaction to Getino?

A: The regulatory label states that the medicine is strictly contraindicated in patients with a known hypersensitivity. The official product information advises that immediate medical attention may be necessary if signs of a severe allergic reaction occur. These signs typically include swelling of the face, lips, tongue, or throat, or difficulty breathing.

Q: What evidence exists for Getino's effectiveness after one year of use?

A: Clinical trials supporting the medicine’s use provide evidence of sustained therapeutic benefits for long-term, continuous treatment. Official study summaries include data on viral suppression and quality of life for periods extending multiple years.

Q: How quickly does Getino typically start working?

A: The active compound is rapidly absorbed, with official pharmacokinetic data indicating it reaches peak blood levels in about 1 to 2 hours after administration. However, the time until a stable clinical effect on the overall viral load is observed can vary among individuals.

Q: Does Getino interact with common over-the-counter pain relievers?

A: Regulatory documents indicate that the medicine should generally be used with caution, or may be avoided, in situations involving co-administration of high-dose or multiple non-steroidal anti-inflammatory drugs (NSAIDs). This is to mitigate the documented risk of new or worsening renal (kidney) impairment.

Q: Can individuals with liver conditions use Getino?

A: Official prescribing information states that the use of this medicine should be administered cautiously in patients with pre-existing liver disease. While no dose adjustment is typically required, close monitoring of liver function by a healthcare professional may be required.

Q: Does Getino affect birth control pills?

A: Clinical studies of this medicine taken with a combined oral contraceptive (COC) have shown no clinically significant drug interactions. Official regulatory information indicates that no dose adjustment for the oral contraceptive is required.

Q: Are there any specific dietary restrictions to follow while on Getino?

A: No specific dietary restrictions are listed in the regulatory label. The tablets are officially instructed to be taken without regard to food, though taking them with a meal may increase the medicine's absorption.

Q: What should I do if the medicine looks slightly different (e.g., color change)?

A: Official guidance requires the medicine to be stored in its original, tightly closed container, protected from moisture and light. If you notice any significant, unexpected change in the appearance of the tablets, official guidance advises consulting a pharmacist immediately and typically recommends against taking the affected dose.

Q: What if I vomit shortly after taking Getino?

A: Specific regulatory guidance for administration addresses this. If vomiting occurs within one hour of administration, a replacement dose may be advised. If vomiting occurs more than one hour after administration, official guidance typically indicates that a replacement dose is not required.

Q: Can I crush or split the Getino tablets?

A: The official product label contains no information supporting the practice of crushing or splitting the tablets. For this reason, this method of administration is not recommended. An oral powder formulation is available for patients who cannot swallow the intact tablet.

Q: Is there a specific lab test needed before starting Getino?

A: Yes, the regulatory label officially recommends specific screening and assessment before starting this medicine. This typically includes screening for HIV-1 infection and assessment of one's renal (kidney) function.

Q: Is the medication Getino gluten-free?

A: The active ingredient is not derived from gluten-containing sources. Official product information lists all inactive ingredients (excipients), which generally do not include gluten or gluten-derived materials.

Q: Does Getino contain any known allergens like lactose?

A: The official product information will list all inactive ingredients, or excipients. Individuals may wish to review this list with their pharmacist for known common allergens such as lactose, which is a common excipient in some tablet formulations.

Q: Does alcohol consumption affect how Getino works?

A: No specific pharmacokinetic interaction with alcohol is reported in the regulatory documentation. However, due to the drug class's documented risk of severe liver side effects like lactic acidosis, a history of alcohol abuse requires caution and close monitoring.

How should Getino be stored and disposed of?

How to Store and Dispose of Getino?

Getino (Tenofovir Disoproxil Fumarate) must be stored strictly according to the conditions defined in regulatory labeling to maintain its chemical stability.

Storage Requirement Condition Defined by Official Documents
Temperature Range Store at 25 C (77 F), with permitted short excursions up to 30 C (86 F).
Environmental Protection Protect from moisture and light; keep away from excess heat.
Container Requirements Keep the medicine in its original container and ensure the container is tightly closed.
Child Safety Keep out of the sight and reach of children.

Official Disposal Instructions

Disposal of unused or expired Getino must follow established regulatory guidelines. The product should be discarded in accordance with local and national regulations for pharmaceutical waste. Individuals should consult a healthcare professional or pharmacist regarding available drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Getino found in:

A-Z Index: